China-based AUSTAR has worked with a validation platform to help two large drug manufacturers in China
AUSTAR, a technology-based pharmaceutical engineering solutions provider, and ValGenesis, an enterprise validation lifecycle management systems (VLMS), have partnered to deploy digital, risk-based validation lifecycle management solutions for life sciences companies in China.
AUSTAR is a technology-based pharmaceutical engineering solution provider with deep understanding of industry regulations and processes. Integrating global high-quality resources and being committed to helping clients improve process and operational effectiveness. Through boosting global drug safety and efficacy to protect and promote human health.
ValGenesis'end-to-end digital validation platform, which includes its flagship VLMS offering, helps the world’s leading life sciences companies enable stronger compliance, enforce standardisation, and further digital transformation across manufacturing operations.
ValGenesis and AUSTAR recently implemented ValGenesis iRisk at two large drug manufacturing centres in China, helping them strengthen risk and compliance across development and manufacturing operations. ValGenesis iRisk helps companies effectively assess and manage risk throughout a product’s lifecycle in a fully digital, purpose-built application.
"ValGenesis and AUSTAR are committed to helping companies assess their risks the way they need to assess them to remain compliant,” said Bo Olsen, ValGenesis SVP of Partners. "iRisk unifies all risk-related activities in one powerful platform, standardizing risk management practices across an organization. We look forward to taking this powerful solution to more life sciences companies in China, with AUSTAR.”
"AUSTAR is committed to serving pharmaceutical enterprises to achieve compliance, quality improvement and risk management,” added Lena Wang, AUSTAR VP. "Through the cooperation with ValGenesis, we will provide more effective information solutions and consulting services.”